118233-29-7

Upstream product

• 34985-37-0 (S)-2-methylbutylamine 
• 103322-58-3 ethyl 4(S)-<(tert-butyloxycarbonyl)amino>-5-(cyclohexylmethyl)-2,2-difluoro-3(R)-hydroxypentanoate 
• 118233-28-6 (3R,4S)-4-tert-Butoxycarbonylamino-5-cyclohexyl-2,2-difluoro-3-hydroxy-pentanoic acid 
• 98105-42-1 (S)-2-(t-butoxycarbonylamino)-3-cyclohexyl-1-propanal 

Downstream Products

• 118233-30-0 (3R,4S)-4-Amino-5-cyclohexyl-2,2-difluoro-3-hydroxy-pentanoic acid ((S)-2-methyl-butyl)-amide; hydrochloride 
• 130406-00-7 N-<(8-propyl-6-pyridin-3-yl-1,2,4-triazolo<4,3-a>pyrazin-3-yl)-acetyl>-(3R,4S)-4-amino-5-cyclohexyl-2,2-difluoro-3-oxopentanoic acid (S)-2-methylbutylamide 
• 130405-95-7 N-<(8-propyl-6-pyridin-3-yl-1,2,4-triazolo<4,3-a>pyrazin-3-yl)-acetyl>-(3R,4S)-4-amino-5-cyclohexyl-2,2-difluoro-3-hydroxypentanoic acid (S)-2-methylbutylamide 
• 137429-63-1 N-(1-piperazinylsulfonyl)-L-phenylalanyl-N-<1(S)-(cyclohexylmethyl)-3,3-difluoro-4-<(2-methylbutyl)amino>-2,4-dioxobutyl>-4,5-didehydro-L-norvalinamide 
• 137302-80-8 N-<<4-<(1,1-dimethylethoxy)carbonyl>-1-piperazinyl>sulfonyl>-L-phenylalanyl-N-<1(S)-(cyclohexylmethyl)-3,3-difluoro-4-<(2-methylbutyl)amino>-2,4-dioxobutyl>-4,5-didehydro-L-norvalinamide 
• 137302-72-8 N-<<4-<(1,1-dimethylethoxy)carbonyl>-1-piperazinyl>sulfonyl>-L-phenylalanyl-N-<1-(cyclohexylmethyl)-3,3-difluoro-2(R)-hydroxy-4-<(2-methylbutyl)amino>-4-oxobutyl>-4,5-didehydro-L-norvalinamide 
• 137302-37-5 N-(4-morpholinylsulfonyl)-L-phenylalanyl-N-<1(S)-(cyclohexylmethyl)-3,3-difluoro-4-<(2-methylbutyl)amino>-2,4-dioxobutyl>-4,5-didehydro-L-norvalinamide 
• 137302-32-0 N-(4-morpholinylsulfonyl)-L-phenylalanyl-N-<1(S)-(cyclohexylmethyl)-3,3-difluoro-2(R)-hydroxy-4-<(2-methylbutyl)amino>-4-oxobutyl>-4,5-didehydro-L-norvalinamide 

Relevant academic research and scientific papers

Design and Synthesis of Potent, Selective, and Orally Active Fluorine-Containing Renin Inhibitors

A series of primate renin inhibitors containing difluorocarbinol and difluoroketone groups at the P1 - P1' position have been synthesized and studied both in vitro and in vivo.In vitro, the compounds were evaluated as inhibitors of m

1,2,4-Triazolopyrazine Derivatives with Human Renin Inhibitory Activity. 3. Synthesis and Biological Properties of Aminodeoxystatine and Difluorostatone Derivatives

Two series of 1,2,4-triazolopyrazine derivatives with human renin inhibitory activity have been synthesized which incorporate the transition-state mimetics (3S,4S)- and (3R,4S)-5-cyclohexyl-3,4-diaminopentanoic acid ((S)- and (R)-CDAPA), and (4S)-4